Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)’s stock price traded up 8.5% on Wednesday . The stock traded as high as $45.93 and last traded at $45.36, 1,212,300 shares traded hands during trading. An increase of 65% from the average session volume of 734,653 shares. The stock had previously closed at $41.80.

BHVN has been the subject of a number of research reports. Goldman Sachs Group set a $89.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Oppenheimer set a $68.00 price objective on Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, June 19th. Cantor Fitzgerald set a $87.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Canaccord Genuity set a $80.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 26th. Finally, ValuEngine lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, June 19th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $69.36.

The firm’s 50-day moving average price is $40.27 and its 200 day moving average price is $49.71. The firm has a market cap of $2.15 billion, a P/E ratio of -7.38 and a beta of 0.32.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.09) by ($0.26). As a group, research analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -7.51 earnings per share for the current year.

In other news, Director Gregory Bailey bought 5,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average cost of $37.65 per share, with a total value of $188,250.00. Following the completion of the transaction, the director now directly owns 2,587,601 shares in the company, valued at approximately $97,423,177.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James Engelhart bought 2,500 shares of the company’s stock in a transaction dated Thursday, June 27th. The stock was purchased at an average cost of $43.05 per share, for a total transaction of $107,625.00. The disclosure for this purchase can be found here. Insiders have purchased 22,500 shares of company stock valued at $900,675 in the last ninety days. Company insiders own 23.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Manchester Capital Management LLC acquired a new stake in Biohaven Pharmaceutical during the 1st quarter valued at $52,000. Tower Research Capital LLC TRC purchased a new position in shares of Biohaven Pharmaceutical during the second quarter valued at $65,000. Aperio Group LLC purchased a new position in shares of Biohaven Pharmaceutical during the second quarter valued at $71,000. Glen Harbor Capital Management LLC raised its position in Biohaven Pharmaceutical by 165.9% during the second quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock valued at $76,000 after buying an additional 1,088 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Biohaven Pharmaceutical by 94.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,256 shares of the company’s stock valued at $99,000 after buying an additional 1,097 shares during the period. 90.93% of the stock is owned by hedge funds and other institutional investors.

About Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Read More: What is a death cross?

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.